Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia by Yaling Liu et al.
RESEARCH Open Access
Dietary phosphate supplement does not
rescue skeletal phenotype in a mouse
model for craniometaphyseal dysplasia
Yaling Liu1, Eliane H. Dutra2, Ernst J. Reichenberger3 and I-Ping Chen1,4*
Abstract
Background: Mutations in the human progressive ankylosis gene (ANKH; Mus musculus ortholog Ank) have been
identified as cause for craniometaphyseal dysplasia (CMD), characterized by progressive thickening of craniofacial
bones and flared metaphyses of long bones. We previously reported a knock-in (KI) mouse model (AnkKI/KI) for CMD
and showed transiently lower serum phosphate (Pi) as well as significantly higher mRNA levels of fibroblast growth
factor 23 (Fgf23) in AnkKI/KI mice. FGF23 is secreted by bone and acts in kidney to promote Pi wasting which leads
to lower serum Pi levels. Here, we examined whether increasing the Pi level can partially rescue the CMD-like
skeletal phenotype by feeding Ank+/+ and AnkKI/KI mice with high Pi (1.7 %) diet from birth for 6 weeks. We studied
the Pi metabolism in AnkKI/KI mice and CMD patients by examining the Pi regulators FGF23 and parathyroid
hormone (PTH).
Results: High Pi diet did not correct CMD-like features, including massive jawbone, increased endosteal and
periosteal perimeters and extensive trabeculation of femurs in AnkKI/KI mice shown by computed microtomography
(μCT). This unexpected negative result is, however, consistent with normal serum/plasma levels of the intact/active
form of FGF23 and PTH in AnkKI/KI mice and in CMD patients. In addition, FGF23 protein expression was
unexpectedly normal in AnkKI/KI femoral cortical bone as shown by immunohistochemistry despite increased mRNA
levels for Fgf23. Renal expression of genes involved in the FGF23 bone-kidney axis, including mFgfr1, mKlotho,
mNpt2a, mCyp24a1 and m1αOHase, were comparable between Ank+/+ and AnkKI/KI mice as shown by quantitative
real-time PCR. Different from normal FGF23 and PTH, serum 25-hydroxyvitamin D was significantly lower in AnkKI/KI
mice and vitamin D insufficiency was found in four out of seven CMD patients.
Conclusions: Our data suggests that FGF23 signaling and Pi metabolism are not significantly affected in CMD and
transiently low Pi level is not a major contributor to CMD.
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Background
Craniometaphyseal dysplasia (CMD), a rare genetic bone
disorder, is characterized by progressive thickening of
craniofacial bones and flared metaphyses of long bones
[1]. CMD patients frequently suffer from hearing loss,
visual impairment, facial paralysis and severe headaches
due to consequences from neuronal compression as a re-
sult of hyperostosis of craniofacial bones [2, 3]. Treatment
for CMD is currently limited to risky surgery to relieve
neurologic symptoms, mainly because its pathogenesis is
not well understood. A major hurdle for studying CMD and
many other rare genetic bone disorders is the unavailability
of specimens for research. We previously generated a
knock-in (KI) mouse model by introducing a Phe377del
mutation in Ank (progressive ankylosis gene), one of the
most commonly identified mutations in CMD patients [4].
Homozygous AnkKI/KI mice replicate many features of CMD
patients, including hyperostostic craniofacial bones, massive
jaw bones, flared metaphyses with extensive trabeculation
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and fusion of middle ear bones [4]. AnkKI/KI mice differ from
CMD patients in joint stiffness of elbows, knees, paws and
vertebrae. This difference could be due to the autosomal
dominant nature of ANK mutations in CMD patients and
the mice we study are homozygous for the mutation.
Heterozygous Ank+/KI mice do not have joint stiffness and
only develop an intermediate skeletal CMD phenotype as
they age [4]. Interestingly, AnkKI/KI mice present with signifi-
cantly lower serum phosphate (Pi) levels at the age of
6 weeks but recover with age. AnkKI/KI mice display remark-
ably increased fibroblast growth factor 23 (Fgf23) mRNA
expression in bones and develop hypomineralization of
bones [5].
FGF23, a phosphaturic factor, is secreted by bone and
acts in kidney to promote Pi wasting. It decreases 1,25-
(OH)2D3 by reducing expression of 1-α hydroxylase,
Npt2a/2c (Na-Pi transporter) and by increasing the 24-
hydroxylase level upon binding to its receptor Fgfr1 and
co-receptor Klotho [6, 7]. Overexpression of FGF23 in
mice leads to hypophosphatemia, hypomineralization,
rickets and decreased 1,25-(OH)2D3, whereas ablation of
FGF23 in mice leads to hyperphosphatemia, soft tissue
calcification and increased 1,25-(OH)2D3 [8, 9]. Al-
though much research has been done on FGF23, its role
in the pathogenesis of CMD has never been addressed.
Mutations for the autosomal dominant form of CMD
have been identified in the human progressive ankylosis
gene (ANKH, encoding ANK), which is a known pyro-
phosphate (PPi) transporter [10, 11]. ANK controls Pi/PPi
homeostasis together with plasma cell membrane glyco-
protein (PC-1, encoded by ectonucleotide pyrophospha-
tase Enpp1), which generates PPi from nucleoside
triphosphates (ATP) and tissue nonspecific alkaline
phosphatase (TNAP, encoded by Tnap), which hydrolyzes
extracellular PPi (ePPi) to generate Pi. The physiological
concentration of ePPi in bone acts as a potent inhibitor of
hydroxyapatite mineralization while supersaturation of
ePPi leads to calcium pyrophosphate dehydrate (CPPD)
crystal formation. Ank knock-out (AnkKO/KO) mice exhibit
joint stiffness due to the lack of PPi transporter, which
results in excessive hydroxyapatite deposition in joints
[12]. Pi is a major component of hydroxyapatite and pro-
motes mineralization. A tightly controlled balance between
extracellular Pi and PPi is required to maintain normal skel-
etal mineralization. CMD mutations in ANK result in re-
duced PPi-transport activity when overexpressed in oocytes
[13]. How changes of Pi levels affect skeletal phenotypes in
CMD and whether Pi can be used to treat CMD in mice or
human have not been investigated.
The only source of Pi is from diet and Pi homeostasis
is mainly regulated by three organs, parathyroid gland,
kidney and bone, which produce parathyroid hormone
(PTH), 1,25-(OH)2D3 (calcitriol, vitamin D) and FGF23,
respectively. These three regulatory loops interact with
one another. PTH stimulates Pi excretion and vitamin D
production in kidney and stimulates FGF23 production in
bone. PTH increases Fgf23 expression in calvariae/femurs
and serum FGF23 levels likely via activation of osteoblasts
[14]. Low Pi and vitamin D in turn can inhibit PTH
production. Vitamin D also increases Pi reabsorption and
thus modulates bone formation and resorption. FGF23 in-
creases Pi wasting and decreases vitamin D production.
Vitamin D increases FGF23 production in bone and FGF23
acts as a counter-regulatory hormone to prevent the hyper-
phosphatemic effects of excess vitamin D [15, 16].
In order to study the involvement of Pi metabolism in
CMD, we examined the levels of FGF23, PTH and 1,25-
(OH)2D3 in a knock-in mouse model for CMD and in
plasma collected from seven CMD patients. We fed mice
with high Pi diet to evaluate whether the transiently
lower serum Pi contributes to skeletal abnormalities in
CMD and whether supplying increased dietary Pi ame-
liorates skeletal phenotypes of AnkKI/KI mice. Our results
showed that Pi regulators were only mildly changed in




A mouse model with a deletion of TTC1130–1132 (phenyl-
alanine 377) in exon 9 of Ank has been previously shown
to replicate many features of human CMD [4]. Mice
were bred from 129/Sv into a C57Bl/J6 background (N5)
for skeletal analysis. High phosphate diet (1.5 %) (Harlan
Teklad) was provided to mothers with litters after birth.
Offspring were continuously fed with the modified diet
for another 3 weeks after weaning. Thus, mice were fed
with high Pi diet for a total of 6 weeks. Normal mouse
chow contained 0.7 % phosphorus. The animal protocol
(100782–1116) was approved by the Institutional Animal
Care and Use Committee (IACUC) of University of Con-
necticut Health and all work was performed in an AAA-
LAC accredited facility.
Biochemical analysis
Blood of mice was obtained from the submandibular
vein (Goldenrod animal lancet; Braintree Scientific) and
collected in Microtainer tubes (Becton Dickinson). Fast-
ing mouse sera were prepared from 3-, 10- and 16-
week-old male Ank+/+ and AnkKI/KI mice. Fasting human
plasma was obtained from seven CMD patients. Re-
search involving human subjects has been approved by
the University of Connecticut Health Institutional Re-
view Board (IRB number: 03-008-1) and written in-
formed consent has been obtained from all participants.
Concentrations of mouse intact FGF23 (mouse intact
FGF23 ELISA kit; Kainos), mouse C-terminal FGF23
form (mouse FGF23 C-terminal ELISA kit; Immutopics),
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human intact FGF23 and C-terminal FGF23 form
(human FGF23 intact ELISA kit, human FGF23 C-
terminal ELISA kit; Immutopics), mouse/human 25-
hydroxy vitamin D (25-hydroxy vitamin D kit; IDS),
mouse and human intact PTH (mouse and human intact
PTH ELISA kit; Immutopics) were determined accord-
ing to manufacturers’ instructions.
Immunohistochemistry
Femurs from 16-week-old male Ank+/+ and AnkKI/KI mice
were dissected, fixed in 4 % paraformaldehyde, decalcified
in 14 % ethylenediaminetetraacetic acid, processed and
embedded in paraffin. Series of 5 μm sections were
collected using the central vein as marker. Briefly, the sec-
tions were pretreated with peroxidase blocking reagent,
blocked with 1 % bovine serum albumin and 5 % normal
goat serum for 30 min at room temperature and incu-
bated with primary FGF23 antibody (1:50 dilution;
MAB26291; R&D Systems). After washing, the sections
were incubated with anti-rat HRP substrate and DAB
(Vector Labs) and counterstained with methyl green.
Isotype rat IgG2a control (R&D Systems) and femoral sec-
tions from FGF23 null mice (a kind gift of Dr. Beate
Lanske) were used as negative controls for antibody speci-
ficity. The percentage of FGF23-positive cells over total
osteocytes in cortical bones (from just below the growth
plate to mid femurs) was determined.
Quantitative real-time PCR (qPCR)
Total RNA from 16-week-old Ank+/+ and AnkKI/KI kidney
tissues was isolated with TRIzol (Invitrogen) according to
manufacturer’s instructions. RNA was treated with DNase
I (Invitrogen) and cDNA was synthesized using Super-
script II reverse transcriptase (Invitrogen). qPCR using
Power SYBR Master Mix (Life Technologies) was
performed in an ABI-7300 thermocycler (Applied Biosys-
tems). PCR efficiency was optimized and primer specificity
was tested by melting curve analysis. Relative quantifica-
tion of gene expression was determined using the ΔΔCt
method by normalizing with 18S RNA. Data was pre-
sented as fold-increase relative to Ank+/+ samples. PCR
primer sequences are listed in Table 1.
μCT analysis
Mandibles and femurs from mice fed with normal and
high Pi diet for 6 weeks after birth were evaluated by
μCT at the μCT Core Facility at UConn Health (mCT20;
ScanCo Medical). For mandibles, the total volume (TV)
and bone volume (BV) were measured. For femurs, the
metaphyseal trabeculation and cortical bone parameters
were measured as described previously [4].
Statistical analysis
Statistical analysis was performed by Student’s t-test or
analysis of variance (ANOVA) using Prism 5 software
(GraphPad Software). Data was presented as mean ±
standard deviation and statistically significant difference
was considered for p < 0.05.
Results
Effects of high Pi diet on skeleton of AnkKI/KI mice
We previously showed that serum Pi levels were de-
creased in 6-week-old AnkKI/KI mice fed with regular
diet (Ank+/+ = 6.622 ± 1.102 mg/dl, n = 10; AnkKI/KI =
5.494 ± 0.893 mg/dl, n = 11; p < 0.05) and were normal in
10-week-old AnkKI/KI mice [4]. To examine whether diet-
ary Pi can rescue the CMD-like skeletal phenotype, we fed
high Pi diet (1.5 %) to Ank+/+ and AnkKI/KI mice continu-
ously for 6 weeks after birth. Serum Pi levels in mice fed
with high Pi diet for 6 weeks did increase (Ank+/+ = 7.554 ±
0.745 mg/dl, n = 9; AnkKI/KI = 6.799 ± 0.771 mg/dl, n = 7)
but no significant difference between Ank+/+ and AnkKI/KI
mice was detected.
High Pi diet in general resulted in a tendency of more tra-
becular bone, decreased sub-periosteal and sub-endosteal
areas, decreased cortical porosity in femurs and increased
bone volume in mandibles of Ank+/+ and AnkKI/KI mice.
Differences between Ank+/+ and AnkKI/KI femurs in meta-
physeal trabeculation, measured by bone volume fraction
(BVF), trabecular number, trabecular thickness and trabecu-
lar space, were abolished by high Pi diet mainly because of
increased bone volume in Ank+/+ mice. The extended trabe-
culation extending into the diaphysis of AnkKI/KI club-
shaped femurs remained the same with the high Pi diet
(Fig. 1). These mice continued to have massive jawbones,
club-shaped femurs, extensive trabeculation, increased cor-
tical porosity and decreased tissue density of femurs when
Table 1 Amplification primers for qPCR
Gene Forward primer Reverse primer
Fgfr1 5'- CCAGTGCATCCATGAACTCTGGGGTTCTCC-3' 5'- GGTCACACGGTTGGGTTTGTCCTTATCCAG -3'
Klotho 5′- CTGGCTAAGGTTCAAGTACGGAGACCTCCC −3′ 5'- GGAGCTGAGCGATCACTAAGTGAATACGCA -3'
Npt2a 5'- CTCATTGTGGGTGCCCAACATGATG -3' 5'- ACCATGTGTCTCCCACGGACTGGAAG -3'
Cyp24a1 5'- CTGCCCCATTGACAAAAGGC -3' 5'- CTCACCGTCGGTCATCAGC -3'
1αOHase 5'- TCAGATGTTTGCCTTTGCCC -3' 5'- TGGTTCCTCATCGCAGCTTC -3'
18S 5'-TTGACGGAAGGGCACCACCAG-3' 5'-GCACCACCACCCACGGAATCG-3'
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compared to Ank+/+ mice. Skeletal features analyzed by μCT
are summarized in Table 2 and Fig. 1.
FGF23 expression in AnkKI/KI mice
To determine whether increased Fgf23 mRNA led to in-
creased FGF23 protein levels, we performed immunohis-
tochemistry with FGF23 antibodies on femoral sections
from 16-week-old mice. To confirm specificity of the
FGF23 antibody, we included femurs from FGF23 null
mice as negative controls. The percentage of FGF23-
positive cells normalized to total osteocytes in cortical
bones was determined. Unexpectedly, there was no sig-
nificant difference in the percentage of FGF23-positive
osteocytes in femoral cortical bones between Ank+/+ and
AnkKI/KI mice (Fig. 2a).
Intact FGF23 protein will become inactive after being
cleaved. To examine whether the discrepancy between
mRNA and protein levels of FGF23 in AnkKI/KI mice is
due to increased proteolytic processing of FGF23, we in-
vestigated FGF23 serum levels in male mice at ages 3, 10
and 16 weeks by ELISA using antibodies recognizing the
full-length FGF23, which is the biologically active form,
or antibodies recognizing both full-length and C-
terminal fragments of FGF23. Cleaved FGF23 is the in-
active form. AnkKI/KI mice showed a trend but no statis-
tical significance in the increase of intact FGF23 but a
significant increase in the inactive C-terminal fragment
of FGF23 suggesting that more FGF23 is processed in
AnkKI/KI mice. This significant increase is only observed
in 16-week-old AnkKI/KI mice but not at ages of 3 or
10 weeks (Fig. 2b).
Galnt3, a GalNac-transferase, prevents the proteolytic
processing of FGF23 by mediating the glycosylation of a
furin-like convertase recognition sequence in FGF23
[17]. To examine whether increased serum C-terminal
FGF23 in AnkKI/KI mice is due to changes in Galnt3
gene expression, we examined Galnt3 mRNA expression
by qPCR and found comparable levels of Galnt3 be-
tween Ank+/+ and AnkKI/KI mice (Fig. 2c). This finding
indicates that the increased C-terminal form of FGF23
in AnkKI/KI mice is likely Galnt3-independent. The activ-
ity of GALNT3 protein or other mechanisms regulating
post-translational modification of FGF23 will need fur-
ther investigation.
Renal expression of genes involved in FGF23 bone-kidney
axis
The kidney plays an important role in regulating Pi
homeostasis and is a target of FGF23. To determine if
the increasing trend of the active form of FGF23 in
AnkKI/KI serum, though not significant, can lead to
changes within kidneys, we first examined the ratio of
kidney weight over total body weight in Ank+/+ and
AnkKI/KI mice. AnkKI/KI mice showed increased kidney/
Fig. 1 μCT images of femurs and mandibles. Representative μCT 3D reconstruction images of femurs and sagittal planes through furcation of first
molar of mandibles from 6-week-old male Ank+/+ and AnkKI/KI mice fed with normal or high Pi diet. (Ank+/+ mice with normal diet n = 4; AnkKI/KI
mice with normal diet n = 5; Ank+/+ mice with high Pi diet, n = 7; AnkKI/KI mice with high Pi diet, n = 8)
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body weight ratio compared to Ank+/+ mice at the age of
16 weeks, however, this was likely due to remarkably de-
creased body weight rather than kidney hypertrophy
since no abnormal morphologic structures in kidneys of
AnkKI/KI mice were observed by H&E staining (Table 3;
data not shown). To study whether the renal expression
of genes targeted by FGF23 are affected in AnkKI/KI mice,
qPCR with specific primers to Fgfr1 (FGF23 receptor),
Klotho (FGF23 co-receptor), Npt2a (sodium phosphate
co-transporter), Cyp24a1 (1α-hydroxy-vitamin D 24-
hydroxylase) and Cyp27b1 (1a(OH)ase, 1α-hydroxylase)
was performed. Kidney mRNA isolated from both 10-
week-old (data not shown) and 16-week-old Ank+/+ and
AnkKI/KI mice was examined. Our results showed a trend
of decreased expression of 1a(OH)ase, Npt2a, Klotho and
a trend of increased expression of Cyp24a1 in 16-week-
old AnkKI/KI mice, however, none of them was statistically
significant (Fig. 3).
PTH and 25(OH) vitamin D in mouse serum
Parathyroid hormone (PTH), 1,25-(OH)2D3 (calcitriol)
and FGF23 interact to maintain Pi homeostasis. We previ-
ously reported lower Pi serum levels and normal PTH in
AnkKI/KI mice at the age of 6 weeks. However, the lower Pi
serum level was within normal range as mice aged to
10 weeks and older [5]. Because we found an increasing
tendency of the active form of FGF23 in AnkKI/KI mice as
they aged, we decided to measure serum PTH and 25-
hydroxy vitamin D at ages of 10 weeks and 16 weeks. 25-
hydroxy vitamin D (25OHD) is a pre-hormone that is
converted into 1,25-(OH)2D3 in the kidneys and is
considered the best indicator of vitamin D status. Serum
PTH levels were comparable between Ank+/+ and AnkKI/KI
mice (10 weeks PTH, Ank+/+:AnkKI/KI = 238.25 ± 135.66
(pg/ml) (n = 19) : 217.83 ± 99.01(pg/ml) (n = 16); 16 weeks
PTH, Ank+/+:AnkKI/KI = 222.13 ± 66.8 (pg/ml) (n = 5) :
242.98 ± 59.8 (pg/ml) (n = 5)). 25OHD was significantly
reduced at the age of 10 weeks (Ank+/+:AnkKI/KI = 41.5 ±
6.61 (ng/ml) (n = 13) : 32.01 ± 2.96 (ng/ml) (n = 12), p <
0.05) but not at 16 weeks (Ank+/+: AnkKI/KI = 41.21 ± 7.42
(ng/ml) (n = 9) : 36.83 ± 5.79 (ng/ml) (n = 12), p = 0.16).
Biochemical analysis of plasma from CMD patients
We determined plasma levels of hormones that are af-
fecting or are affected by Pi homeostasis in seven CMD
patients (Table 4). PTH and the intact and C-terminal
forms of FGF23 were normal in CMD patients. Four out
of seven CMD patients had insufficiency or deficiency of
vitamin D measured by 25OHD.
Discussion
Pi metabolism plays an important role in the regulation of
skeletogenesis [18]. Serum Pi levels in CMD patients have
been reported as transiently lower or normal [19–21]. Con-
sistently, we observed lower serum Pi levels in AnkKI/KI
mice at the age of 6 weeks but serum Pi levels were normal
in 10-week-old AnkKI/KI mice [5]. Interestingly, mild hypo-
phosphatemia has also been associated with patients ex-
pressing a homozygous ANKH missense mutation
(Leu244Ser) and presenting mental retardation, hearing
loss, ankylosis, periarticular ligament ossification, entheso-
pathy, and dentinogenesis imperfecta [22].
Table 2 μCT analysis of 6-week-old male Ank+/+ and AnkKI/KI mice fed with normal and high Pi diet
Normal Pi High Pi
Parameters Ank+/+(n = 4) AnkKI/KI (n = 5) Ank+/+(n = 7) AnkKI/KI (n = 8)
Mandible
Total volume (mm3) 0.28 ± 0.01 0.42 ± 0.02c 0.31 ± 0.01a 0.51 ± 0.04b, c
Bone volume (mm3) 0.18 ± 0.02 0.31 ± 0.03c 0.23 ± 0.001a 0.44 ± 0.04b, c
BVF (%) 66.5 ± 0.2 77.4 ± 2.2c 74 ± 2.3a 86 ± 0.01b, c
Femur trabecular bone (metaphyses)
BVF (%) 5.9 ± 0.4 9.1 ± 0.4c 9.7 ± 3.1 9.9 ± 2.3
Trabecular number (N/mm) 4 ± 0.01 5.3 ± 0.12c 5.27 ± 0.81a 5.66 ± 0.48
Trabecular thickness (μm) 34 ± 2.4 37.6 ± 0.86c 36.2 ± 2.5 36.6 ± 2.2
Trabecular Spacing (μm) 248.53 ± 19.49 186.9 ± 5.62c 193.19 ± 32.10a 173.35 ± 15.68
Femur cortical bone (diaphyses)
Subperiosteal area (mm2) 1.64 ± 0.11 2.26 ± 0.22c 1.20 ± 0.32a 1.7 ± 0.10b, c
Subendosteal area (mm2) 1.05 ± 0.06 1.46 ± 0.16c 0.88 ± 0.14 1.18 ± 0.09c
Cortical porosity (%) 0.4 ± 0.2 1.95 ± 0.01c 0.4 ± 0.23 1.16 ± 0.01c
Tissue density (mg/cm3 HA) 1135.0 ± 30.9 1125.0 ± 13.5c 1141.6 ± 11.1 1106.4 ± 16.1c
BVF: bone volume fraction (bone volume/total volume)(%); ap < 0.05: statistical significance between Ank+/+ mice fed with normal and Pi diet;b p < 0.05: statistical
significance between AnkKI/KI mice fed with normal and Pi diet;c p < 0.05: statistical significance between Ank+/+ and AnkKI/KI mice fed with the same diet. Data
are mean ± SD
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In order to study whether Pi metabolism is abnormal
in mice and patients with CMD and whether dietary Pi
affects the bone phenotype in the CMD mouse model
we utilized high Pi diet in mice to examine the effects of
Pi on the bone phenotype. We compared Ank+/+ and
AnkKI/KI littermates fed with normal mouse chow and
high Pi diet. We detected increased serum Pi levels after
feeding mice with high Pi diet for 6 weeks. As expected,
high Pi diet increases the bone volume in general be-
cause Pi is required for hydroxyapatite (calcium phos-
phate) formation. Pi can also affect osteoclast activity
although its effects remain controversial. It has been
shown that high Pi decreased osteoclastogenesis in vitro
[23]. On the other hand, high Pi diet has been shown to
increase osteoclast numbers in the Hyp mice [24]. Our
Fig. 2 FGF23 in AnkKI/KI mice. a Immunohistochemistry showed no significant difference of FGF23 in femoral cortical bones from 16-week-old Ank
+/+ and AnkKI/KI mice. Femurs stained with isotype IgG antibody and femurs from Fgf23 null mice were used as negative controls. FGF23-positive
cells stained brown. Nuclei are counterstained with methyl green. Histogram shows numbers of FGF23-positive cells normalized to total number
of osteocytes. Ank+/+ n = 5, AnkKI/KI n = 7; Scale bar = 100 μm. b ELISA assays of intact form of FGF23 in serum (top panel) and C-terminal form of
FGF23 (bottom panel) in 3-, 10- and 16-week-old Ank+/+ and AnkKI/KI mice. 3-week-old mice: Ank+/+ n = 7, AnkKI/KI n = 5; 10-week-old Ank+/+ n = 10,
AnkKI/KI =9; 16-week-old Ank+/+ n = 5, AnkKI/KI n = 5. c qPCR of Galnt3 expression in femoral bones of 16-week-old Ank+/+ and AnkKI/KI mice. Data are
mean ± S.D. * p < 0.05
Table 3 Body weight, kidney weight (sum of right and left
kidneys) and the ratio of kidney to body weight in Ank+/+ and
AnkKI/KI mice
Ank+/+ AnkKI/KI
BW 6 weeks 22.83 ± 1.91 (n = 7) 20.83 ± 2.27 (n = 8)
BW 10 weeks 27.35 ± 2.94 (n = 12) 23.46 ± 1.57a (n = 10)
BW 20 weeks 38.37.2 ± 6.3 (n = 10) 20.54 ± 2.96b (n = 6)
KW 6 weeks 359.5 ± 26.8 334.1 ± 53.2
KW 10 weeks 336.3 ± 64.0 297.9 ± 72.7
KW 20 weeks 455.0 ± 68.9 329.5 ± 66.5b
KW/BW 6 weeks 15.75 ± 0.15 16.08 ± 2.17
KW/BW 10 weeks 12.45 ± 2.60 12.69 ± 3.06
KW/BW 20 weeks 12.01 ± 1.54 15.99 ± 2.13b
BW: body weight (g); KW: kidney weight (mg); ap < 0.05, bp < 0.001 between
Ank+/+ and AnkKI/KI mice
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μCT data showed that phenotypic differences between
Ank+/+ and AnkKI/KI mice, including the club-shaped fe-
murs, increased cortical porosity and hyperostosis of
mandibles in AnkKI/KI mice, did not change with high Pi
diet. We therefore, did not further perform static or dy-
namic histomorphometry with these bones. This data indi-
cates that dietary Pi supplement is not efficient in correcting
the CMD phenotype and may be counterproductive.
We examined FGF23 and the FGF23-mediated bone-
kidney axis because we previously found significantly in-
creased Fgf23 mRNA levels in calvarial and femoral
bones of AnkKI/KI mice [5]. FGF23 has been associated
with a number of human diseases, including X-linked
hypophosphatemia (XLH), autosomal dominant hypo-
phosphatemic rickets (ADHR), chronic kidney disease
(CKD), familial tumoral calcinosis, McCune-Albright
syndrome, and fibrous dysplasia of bone [25–29]. Unex-
pectedly, we did not detect significant differences in
FGF23 protein expression in femoral bones or of the ac-
tive form of FGF23 in serum from Ank+/+ and AnkKI/KI
mice. We also did not observe significant pathological
changes in renal morphology or in abnormal mRNA ex-
pression of FGF23-target genes in AnkKI/KI kidneys. Al-
though the mechanisms that would explain the
discrepancy between Fgf23 mRNA and FGF23 protein
levels are yet unknown, our data suggests that increased
Fgf23 transcripts are unlikely the primary factor contrib-
uting to the skeletal phenotype in CMD.
Normalization of serum Pi levels in AnkKI/KI mice as
they age suggests that a feedback mechanism may be
involved to correct the decreased Pi levels as AnkKI/KI
mice age [5]. We therefore examined levels of FGF23,
PTH and 1,25-(OH)2D3 which are regulators known to
control Pi homeostasis [30, 31]. The active form 1,25-
(OH)2D3 results from formation of cholecalciferol in the
skin by photolysis of 7-dehydrocholesterol under sun-
light exposure followed by hydroxylation of cholecalcif-
erol to 25-hydroxy vitamin D (25OHD) in the liver.
25OHD is further hydroxylated in the kidney to form
the active form 1,25-(OH)2D3. Although commercial kits
are available to measure 1,25-(OH)2D3, the vitamin D
status is best determined by 25OHD levels [32, 33]. This
is because 25OHD has a half-life of approximately
3 weeks whereas 1,25(OH)2D3 has a half-life of only 4–6
h. 25OHD is unregulated and can reflect substrate avail-
ability. On the other hand, 1,25-(OH)2D3 is highly regu-
lated and therefore provides limited information about
the vitamin D status. In both, CMD mice and patients
with CMD, we found normal intact FGF23 and PTH
levels. 25OHD was transiently lower in AnkKI/KI mice at
the age of 10 weeks but became comparable to Ank+/+
mice as they aged to 16 weeks. Four out of seven CMD
patients showed vitamin D insufficiency or deficiency.
Lower vitamin D levels may be associated with insuffi-
cient nutritional uptake, reduced sun exposure or the
status of vitamin D binding protein (DBP). A recent
study suggests that a specific type of nucleotide poly-
morphisms in Gc, the gene encoding DBP, is associated
with the highest 25OHD concentration compared to
other lower affinity Gc variants in West African children
Fig. 3 Comparable expression of genes involved in FGF23 bone-kidney axis. qPCR of mFgfr1, mKlotho, mNpt2a, mCyp24a1 and m1αOHase expression
in kidney from 16-week-old Ank+/+ and AnkKI/KI mice. Data are mean ± SD. No significant differences were detected. RQ: relative quantification
Table 4 Biochemical analysis of plasma from CMD patients
Case Ank mutation Age Gender PTH (pg/ml) 25OHD (ng/ml) i-FGF23 (pg/ml) c-FGF23 (RU/ml)
1 F377del 45 F 63.14 32.90 13.42 61.85
2 F377del 17 F 37.38 40.92 19.84 59.02
3 F377del 14 F 31.41 34.26 14.64 50.83
4 F377del 9 F 28.78 29.68 13.71 14.25
5 S375del 10 F 35.57 13.4 33.16 31.95
6 S375del 48 F 26.75 18.56 13.51 30.66
7 C331→ R 18 M 16.53 23.82 10.02 63.25
i-FGF23: intact FGF23; c-FGF23: C-terminal form of FGF23; Normal range of human hormones: 1) human PTH: 12–65 pg/ml; 2) human i-FGF23: 10–50 pg/ml; 3) human c-FGF23:
<120-150 RU/ml. 4) human vitamin D insufficiency: 21–29 ng/ml; vitamin D deficiency < 20 ng/ml. Bold number indicated cases with vitamin D insufficiency or deficiency
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[34]. Further studies will be needed to investigate mech-
anisms leading to decreased vitamin D levels in CMD,
such as whether DBP status is affected by CMD ANKH
mutations. Due to the limited number of CMD cases in
this study no conclusion can be drawn based on bio-
chemical analyses.
There are several limitations to this study. One limita-
tion is that we have samples from only seven CMD
patients of different gender and age because CMD is a
very rare disorder. Secondly, it has been challenging to
recruit healthy age and sex matched subjects as controls
for the individual assays. We thus compared our data to
well-accepted normal ranges of FGF23, PTH and
25OHD. Lastly, the mechanisms of increased cleavage of
FGF23 and transiently decreased vitamin D in AnkKI/KI
mice are still unknown. Nonetheless, this project is sig-
nificant as we show that Pi metabolism is not signifi-
cantly affected and thus is unlikely a major contributor
to CMD. A tight balance between Pi and PPi is import-
ant for regulation of skeletal modeling and remodeling.
CMD mutant ANK has been reported to reduce PPi
transporting activity [13]. Although we found that Pi
metabolism or Pi levels are not severely altered in CMD
mice or patients, adjusting the Pi/PPi ratio might ameli-
orate skeletal abnormalities of CMD. Clinically, patients
can reduce serum Pi levels by avoiding foods that are
high in Pi or by Pi binders, such as aluminum salts, cal-
cium carbonate, calcium acetate and lanthanum carbon-
ate. Future studies will focus on whether a low Pi diet in
AnkKI/KI mice is beneficial for correcting a possibly al-
tered Pi/PPi ratio in CMD, which may be caused by de-
creased PPi.
Conclusions
Our data indicate that the bone-kidney axis of FGF23 is
not a primary contributor to the pathology of CMD.
Levels of circulating PTH and active form of FGF23 are
within the normal range in AnkKI/KI mice and CMD pa-
tients. High Pi diet does not appear to correct the bone
phenotype of CMD.
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